Q-omics provides the consensus-scored BIN2 profile across patient tissues and cancer cell-line models. BIN2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BIN2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, BIN2 protein abundance shows 36,594 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where BIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BIN2 survival associations across molecular data types. BIN2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BIN2 RNA expression–survival associations across cancer types. High BIN2 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BIN2 RNA expression.
This table summarizes BIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BIN2 shows lower tumor expression in COAD, LUSC and LUAD and higher tumor expression in KIRC, KIRP and STAD. The KIRC box plot shows higher BIN2 RNA expression in tumor versus normal tissue (log2 FC = +1.793, t-test p < 0.001).
This table shows molecular features associated with BIN2 in patient tissues and cancer cell lines. In patient samples, BIN2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
